Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.79 |
| ▸ | NPC1 | O15118 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | ACACB | O00763 | 1/20 | 0.63 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949543 | 1.00 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL24862899 | 0.90 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL4103656 | 0.89 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL23099741 | 0.89 | NPC1 (0.74) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL507202 | 0.88 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL17914162 | 0.86 | ATM (0.66) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL17914156 | 0.86 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL25890576 | 0.86 | ACACB (0.67) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL23099898 | 0.85 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL3078645 | 0.85 | LMNA (0.76) | RAB9ANPC1SMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117580841-A | Macrocyclic compounds and uses thereof | 特修斯制药公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-112384517-B | Heteroaryl compounds and uses thereof | 新旭生技股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3102193-B1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | UNIV RUTGERS (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-114736219-A | Antitumor compounds | 法马马有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-108546643-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-02-25 | — | — | CN | disclosed |
| CN-108611384-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-02-25 | — | — | CN | disclosed |
| CN-108504703-B | Process for large scale enzymatic synthesis of oligosaccharides | 中央研究院 | 2021-06-29 | — | — | CN | disclosed |
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| WO-2008098151-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1799684-A2 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1146037-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006041773-A2 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-6410749-B1 | REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND | NIPPON SODA CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1146037-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | CYP51A1, CYP1A2, CYP1A1 | RAB9A 1825/4885NPC1 175/4885SMN1; SMN2 1807/4885 |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | RAB9A 2253/4885NPC1 1495/4885SMN1; SMN2 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.